{"id":8401,"date":"2021-12-16T13:28:00","date_gmt":"2021-12-16T18:28:00","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/lisiraglide-cas-320367-13-3-ar-en-glukagonliknande-peptid-1-glp-1-receptoragonist\/"},"modified":"2021-12-16T13:28:00","modified_gmt":"2021-12-16T18:28:00","slug":"lisiraglide-cas-320367-13-3-ar-en-glukagonliknande-peptid-1-glp-1-receptoragonist","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/sv\/product\/lisiraglide-cas-320367-13-3-ar-en-glukagonliknande-peptid-1-glp-1-receptoragonist\/","title":{"rendered":"Lisiraglide CAS 320367-13-3 \u00e4r en glukagonliknande peptid-1 (GLP-1) receptoragonist"},"content":{"rendered":"

Lisiraglide CAS 320367-13-3 \u00e4r en glukagonliknande peptid-1 (GLP-1) receptoragonist<\/strong><\/h2>\n

Produktnamn: Lixisenatide
\nSynonymer: Lixisenatide, >98%;lixisenatide;Lixisenatide|Lixisenatideacetat;Lixisenatideacetat;Lixisenatide USP\/EP\/BP
\nCAS: 320367-13-31
\n1O67S7N21
\n1MF347S7N
\nMW: 4858.53
\nEINECS:
\nProduktkategorier:
\nMol Fil: 320367-13-3.mol<\/p>\n

Lisiraglid \u00e4r en glukagonliknande peptid-1 (GLP-1) receptoragonist, ett hormon som hj\u00e4lper till att normalisera blodsockerniv\u00e5erna. L\u00e4kemedlets s\u00e4kerhet och effekt utv\u00e4rderades i 10 kliniska pr\u00f6vningar som inkluderade totalt 5 400 patienter med typ 2-diabetes. I dessa studier utv\u00e4rderades lisiramid b\u00e5de som monoterapi och i kombination med andra FDA-godk\u00e4nda diabetesl\u00e4kemedel, inklusive metformin, sulfonylureider, pioglitazon och basalinsulin. I dessa f\u00f6rs\u00f6k f\u00f6rb\u00e4ttrade anv\u00e4ndningen av lisiramid niv\u00e5erna av glykerat hemoglobin (en indikator p\u00e5 blodsockerniv\u00e5er). Dessutom behandlades mer \u00e4n 6 000 patienter med typ 2-diabetes med risk f\u00f6r aterosklerotisk kardiovaskul\u00e4r sjukdom med lisiramid eller placebo i Cardiovascular Outcomes Trial. Anv\u00e4ndning av lisiramid hos dessa patienter \u00f6kade inte risken f\u00f6r kardiovaskul\u00e4ra biverkningar. Lisiragide ska inte anv\u00e4ndas f\u00f6r att behandla patienter med typ 1-diabetes eller patienter med f\u00f6rh\u00f6jda ketoner eller urin i blodet (diabetisk ketoacidos). De vanligaste biverkningarna f\u00f6rknippade med lisiramid \u00e4r illam\u00e5ende, kr\u00e4kningar, huvudv\u00e4rk, diarr\u00e9 och yrsel. Hypoglykemi \u00e4r en annan vanlig biverkning hos patienter som behandlas med lisiramid och andra antidiabetiska l\u00e4kemedel som sulfonureider och\/eller basalgr\u00f6da. Dessutom har allvarliga \u00f6verk\u00e4nslighetsreaktioner (inklusive \u00f6verk\u00e4nslighet) rapporterats i kliniska pr\u00f6vningar med Lisiragib.<\/p>\n

Lixisenatid \u00e4r ett l\u00e4kemedel som f\u00f6r n\u00e4rvarande anv\u00e4nds f\u00f6r att behandla diabetes och \u00e4r ocks\u00e5 en GLP-1-receptoragonist. Lixisenatid (Lyxumia) godk\u00e4ndes f\u00f6r marknadsf\u00f6ring i Europa 2013 och \u00e4r en injicerbar diabetesbehandling baserad p\u00e5 Lixisenatid, som ges en g\u00e5ng om dagen, tillsammans med andra mediciner eller insulin, till patienter vars blodsockerniv\u00e5er endast kan kontrolleras med mediciner.< &>
\n Notering av Lisiraglide CAS 320367-13-3<\/strong>
\nEndast f\u00f6r forskningsanv\u00e4ndning, inte f\u00f6r m\u00e4nskligt bruk<\/p>\n","protected":false},"excerpt":{"rendered":"

Produktnamn: Lixisenatid
\nAcetate;Lixisenatid USP\/EP\/BP
\nCAS: 320367-13-3
\nMF: C215H347N61O65S
\nMW: 4858,53
\nMol Fil: 320367-3,13<\/p>\n","protected":false},"featured_media":2112,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[351],"product_tag":[1273],"class_list":{"0":"post-8401","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-diabetespeptid","7":"product_tag-lisiraglide-cas-320367-13-3-is-a-glucagon-like-peptide-1-glp-1-receptor-agonist-sv","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product\/8401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/comments?post=8401"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/media\/2112"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/media?parent=8401"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_brand?post=8401"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_cat?post=8401"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_tag?post=8401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}